Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116750214> ?p ?o ?g. }
- W2116750214 endingPage "456" @default.
- W2116750214 startingPage "448" @default.
- W2116750214 abstract "Acute myeloid leukemia (AML) continues to represent an area of critical unmet need with respect to new and effective targeted therapies. The Bcl-2 family of pro- and antiapoptotic proteins stands at the crossroads of cellular survival and death, and the expression of and interactions between these proteins determine tumor cell fate. Malignant cells, which are often primed for apoptosis, are particularly vulnerable to the simultaneous disruption of cooperative survival signaling pathways. Indeed, the single agent activity of agents such as mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase kinase (MEK) inhibitors in AML has been modest. Much work in recent years has focused on strategies to enhance the therapeutic potential of the bona fide BH3-mimetic, ABT-737, which inhibits B-cell lymphoma 2 (Bcl-2) and Bcl-xL. Most of these strategies target Mcl-1, an antiapoptotic protein not inhibited by ABT-737. The phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways are central to the growth, proliferation, and survival of AML cells, and there is much interest currently in pharmacologically interrupting these pathways. Dual inhibitors of PI3K and mTOR overcome some intrinsic disadvantages of rapamycin and its derivatives, which selectively inhibit mTOR. In this review, we discuss why combining dual PI3K/mTOR blockade with inhibition of Bcl-2 and Bcl-xL, by virtue of allowing coordinate inhibition of three mutually synergistic pathways in AML cells, may be a particularly attractive therapeutic strategy in AML, the success of which may be predicted for by basal Akt activation." @default.
- W2116750214 created "2016-06-24" @default.
- W2116750214 creator A5013173470 @default.
- W2116750214 creator A5014658692 @default.
- W2116750214 creator A5038004259 @default.
- W2116750214 creator A5061036144 @default.
- W2116750214 date "2014-07-01" @default.
- W2116750214 modified "2023-10-17" @default.
- W2116750214 title "Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML" @default.
- W2116750214 cites W1255676896 @default.
- W2116750214 cites W1487506158 @default.
- W2116750214 cites W1495123612 @default.
- W2116750214 cites W1569244981 @default.
- W2116750214 cites W1591540697 @default.
- W2116750214 cites W1599602125 @default.
- W2116750214 cites W1963713713 @default.
- W2116750214 cites W1965626427 @default.
- W2116750214 cites W1965694831 @default.
- W2116750214 cites W1966233170 @default.
- W2116750214 cites W1966714311 @default.
- W2116750214 cites W1967913221 @default.
- W2116750214 cites W1968612402 @default.
- W2116750214 cites W1970961784 @default.
- W2116750214 cites W1971392223 @default.
- W2116750214 cites W1973166702 @default.
- W2116750214 cites W1974300980 @default.
- W2116750214 cites W1975290731 @default.
- W2116750214 cites W1976577472 @default.
- W2116750214 cites W1977267072 @default.
- W2116750214 cites W1979456040 @default.
- W2116750214 cites W1983470364 @default.
- W2116750214 cites W1984169187 @default.
- W2116750214 cites W1984619334 @default.
- W2116750214 cites W1984621921 @default.
- W2116750214 cites W1986979976 @default.
- W2116750214 cites W1987821813 @default.
- W2116750214 cites W1990408342 @default.
- W2116750214 cites W1990983360 @default.
- W2116750214 cites W1992947847 @default.
- W2116750214 cites W1996122750 @default.
- W2116750214 cites W1999053719 @default.
- W2116750214 cites W2000273667 @default.
- W2116750214 cites W2001404126 @default.
- W2116750214 cites W2001999652 @default.
- W2116750214 cites W2006450622 @default.
- W2116750214 cites W2006771504 @default.
- W2116750214 cites W2007007231 @default.
- W2116750214 cites W2007765910 @default.
- W2116750214 cites W2015512041 @default.
- W2116750214 cites W2017333581 @default.
- W2116750214 cites W2025894164 @default.
- W2116750214 cites W2026450884 @default.
- W2116750214 cites W2027395744 @default.
- W2116750214 cites W2027798317 @default.
- W2116750214 cites W2029098356 @default.
- W2116750214 cites W2030292335 @default.
- W2116750214 cites W2031929368 @default.
- W2116750214 cites W2034983118 @default.
- W2116750214 cites W2038444072 @default.
- W2116750214 cites W2039640090 @default.
- W2116750214 cites W2040429996 @default.
- W2116750214 cites W2041230280 @default.
- W2116750214 cites W2041797768 @default.
- W2116750214 cites W2041811289 @default.
- W2116750214 cites W2045395394 @default.
- W2116750214 cites W2046416127 @default.
- W2116750214 cites W2049482339 @default.
- W2116750214 cites W2052690356 @default.
- W2116750214 cites W2054042776 @default.
- W2116750214 cites W2054917860 @default.
- W2116750214 cites W2061041305 @default.
- W2116750214 cites W2062301404 @default.
- W2116750214 cites W2063853379 @default.
- W2116750214 cites W2067437043 @default.
- W2116750214 cites W2068962767 @default.
- W2116750214 cites W2070732456 @default.
- W2116750214 cites W2072528662 @default.
- W2116750214 cites W2074521790 @default.
- W2116750214 cites W2075740917 @default.
- W2116750214 cites W2076542620 @default.
- W2116750214 cites W2077582389 @default.
- W2116750214 cites W2077813812 @default.
- W2116750214 cites W2078936160 @default.
- W2116750214 cites W2082241903 @default.
- W2116750214 cites W2083557315 @default.
- W2116750214 cites W2084191934 @default.
- W2116750214 cites W2085419794 @default.
- W2116750214 cites W2085803786 @default.
- W2116750214 cites W2087598047 @default.
- W2116750214 cites W2088371348 @default.
- W2116750214 cites W2090982381 @default.
- W2116750214 cites W2093431913 @default.
- W2116750214 cites W2094399892 @default.
- W2116750214 cites W2094546718 @default.
- W2116750214 cites W2097290512 @default.
- W2116750214 cites W2098466954 @default.
- W2116750214 cites W2099110265 @default.
- W2116750214 cites W2102461774 @default.